Capricor Therapeutics To Present Long-Term Data From HOPE-2 Open Label Extension Study At 2024 World Muscle Society Congress October 8-12, 2024
Capricor Therapeutics To Present Long-Term Data From HOPE-2 Open Label Extension Study At 2024 World Muscle Society Congress October 8-12, 2024
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today that the Company will present the three-year safety and efficacy results from its HOPE-2 open-label extension (OLE) study with lead asset deramiocel for treating Duchenne muscular dystrophy (DMD). The data will highlight the long-term, multi-modal benefits of deramiocel in a late-breaking poster presentation at the 29th Annual Congress of the World Muscle Society (WMS 2024), taking place October 8-12, 2024, in Prague, Czechia.
生物技術公司Capricor Therapeutics (納斯達克:CAPR) 宣佈,該公司將於今日公佈其針對罕見疾病開發的轉化性電芯和外泌體療法的三年安全性和有效性結果,這些療法用於治療杜欣氏肌營養不良(DMD)。數據將重點展示其首席資產deramiocel在HOPE-2開放式延展(OLE)研究中的長期、多模式效益,在2024年10月8-12日在捷克布拉格舉辦的第29屆世界肌肉學會年會(WMS 2024)上進行最新突破性海報展示。